<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-39128</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Neolpharma Project</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Founded more than 31 years ago, Grupo Neolpharma (the Company) is a Mexico-based, family-owned, pharmaceutical company focused on the development, manufacture, distribution and sale of branded and unbranded generic medicines.&#xA0; Through its related companies, Neolpharma has presence in Mexico, Puerto Rico, Peru and Ecuador.&#xA0; It exports from Mexico to Colombia, El Salvador, Panama, Costa Rica, Guatemala, Honduras and the Dominican Republic.  Neolpharma owns an active pharmaceutical ingredients (API) production plant, four pharmaceutical finished formulations production plants; one USFDA/EMA approved plant in Puerto Rico; two distribution companies; and a pharmacy chain in Mexico with 47 branches.&#xA0; It is one of the leading domestic pharmaceutical companies in Mexico, primarily focused on prescription generics, with a portfolio of over 250 products in therapeutic areas such as central nervous system, cardiovascular, oncology and diabetes.&#xA0; As of today, it employs approximately 2,485 full-time employees of which 49% are women.  The proposed IFCs financing aims to support Grupo Neolpharmas expansion plan in Mexico, which includes ramping up production capabilities and climate related projects (the Project).</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Increased access to high-quality and low-cost generics: The Project has the potential to increase competitiveness in the pharmaceutical market through the entry and expansion of a generic pharmaceutical manufacturer that will introduce a greater variety of medicine and sell medicine at relatively lower prices than the originator brands. The entry of additional generics companies into markets leads to further price reductions as competitive pressures intensify.

- South-South knowledge transfer: As Neolpharma expands its regional footprint, it will bring new products, more stringent operational and quality practices, as well as knowledge and technology transfer to other countries.

- Employment generation and development of SMEs: with the new injectables plant, Neolpharma expects to generate 500 direct new jobs in Mexico during and after construction phase. The Project will also bring 2,000 indirect employment through the Company&apos;s purchases of goods and services. In addition, the new plant in Toluca will generate 250 direct new jobs.

- Increased exports: the Pharmaceutical sector was officially declared as a strategic export sector for the Government of Mexico (&quot;GoM&quot;). Neolpharma&apos;s growth strategy to expand outside of Mexico is in line with the GoM priorities as it aims at increasing exports and strengthening Mexico&apos;s regional competitiveness.

- High demonstration effect on the importance, technical feasibility and financial sustainability of the API industry: One of Neolpharma&apos;s strategic projects is increasing its API plant&apos;s capacity, which will create a positive demonstration effect on the feasibility and financial sustainability of an API plant.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">NEOLPHARMA, S.A. DE C.V.</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-39128" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2021-03-17" type="1"></activity-date>
  <activity-date iso-date="2021-08-26" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">0  0  0  0  0  0  0  0  0.0000         &#xA0;  Name  :   Diego Ocampo Gutierrez    Address  :&#xA0; Calzada de Tlalpan #4369, Col. Toriello Guerra, Del. Tlalpan, M&#xE9;xico, D.F. C.P. 14050    Email:&#xA0; diego.ocampo@neolpharma.com    Telephone: +52 55 4124-7400</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Neolpharma  Diego Ocampo  Research and Development Director  +52 (55) 4124-7400  diego.ocampo@neolpharma.com  Divisi&#xF3;n del Norte No. 3377, Col. El Rosario, C.P. 04380, Ciudad de M&#xE9;xico  http://www.neolpharma.com</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="MX" percentage="100">
   <narrative xml:lang="EN">Mexico</narrative>
  </recipient-country>
  <location ref="MX-Mexico">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">Mexico</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>23.0000000000 -102.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">other</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $20.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2021-03-17"></period-start>
   <period-end iso-date="2021-06-30"></period-end>
   <value currency="USD" value-date="2021-03-17">20000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-03-17"></transaction-date>
   <value currency="USD" value-date="2021-03-17">20000000</value>
   <receiver-org>
    <narrative xml:lang="EN">NEOLPHARMA, S.A. DE C.V.</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/39128">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/#/projectDetailSII/39128">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
